- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
The marketing authorisation for ProMeris Duo has been withdrawn at the request of the marketing authorisation holder.
ProMeris Duo : EPAR - Summary for the public
English (EN) (231.22 KB - PDF)
български (BG) (268.89 KB - PDF)
español (ES) (234.19 KB - PDF)
čeština (CS) (263.37 KB - PDF)
dansk (DA) (231.6 KB - PDF)
Deutsch (DE) (237.07 KB - PDF)
eesti keel (ET) (231.04 KB - PDF)
ελληνικά (EL) (273.19 KB - PDF)
français (FR) (234.85 KB - PDF)
italiano (IT) (230.99 KB - PDF)
latviešu valoda (LV) (271.61 KB - PDF)
lietuvių kalba (LT) (260.01 KB - PDF)
magyar (HU) (258.27 KB - PDF)
Malti (MT) (269.89 KB - PDF)
Nederlands (NL) (232.34 KB - PDF)
polski (PL) (261.12 KB - PDF)
português (PT) (233.54 KB - PDF)
română (RO) (259.96 KB - PDF)
slovenčina (SK) (264.08 KB - PDF)
slovenščina (SL) (250.13 KB - PDF)
Suomi (FI) (232.08 KB - PDF)
svenska (SV) (233.25 KB - PDF)
Product information
ProMeris Duo : EPAR - Product Information
English (EN) (471.39 KB - PDF)
български (BG) (555.84 KB - PDF)
español (ES) (463.63 KB - PDF)
čeština (CS) (510.99 KB - PDF)
dansk (DA) (459.91 KB - PDF)
Deutsch (DE) (565.04 KB - PDF)
eesti keel (ET) (467.29 KB - PDF)
ελληνικά (EL) (564.31 KB - PDF)
français (FR) (554.89 KB - PDF)
íslenska (IS) (462.33 KB - PDF)
italiano (IT) (606.2 KB - PDF)
latviešu valoda (LV) (595.88 KB - PDF)
lietuvių kalba (LT) (529.65 KB - PDF)
magyar (HU) (592.54 KB - PDF)
Malti (MT) (547.9 KB - PDF)
Nederlands (NL) (466.67 KB - PDF)
norsk (NO) (546.57 KB - PDF)
polski (PL) (634.45 KB - PDF)
português (PT) (565.16 KB - PDF)
română (RO) (532.02 KB - PDF)
slovenčina (SK) (543.1 KB - PDF)
slovenščina (SL) (539.48 KB - PDF)
Suomi (FI) (477.98 KB - PDF)
svenska (SV) (457.92 KB - PDF)
ProMeris Duo : EPAR - All Authorised presentations
English (EN) (146.07 KB - PDF)
български (BG) (197.83 KB - PDF)
español (ES) (145.18 KB - PDF)
čeština (CS) (186.36 KB - PDF)
dansk (DA) (145.68 KB - PDF)
Deutsch (DE) (154.34 KB - PDF)
eesti keel (ET) (145.19 KB - PDF)
ελληνικά (EL) (198.38 KB - PDF)
français (FR) (145.66 KB - PDF)
íslenska (IS) (146.14 KB - PDF)
italiano (IT) (145.84 KB - PDF)
latviešu valoda (LV) (199.11 KB - PDF)
lietuvių kalba (LT) (184.36 KB - PDF)
magyar (HU) (185.85 KB - PDF)
Nederlands (NL) (145.6 KB - PDF)
norsk (NO) (145.55 KB - PDF)
polski (PL) (164.96 KB - PDF)
português (PT) (145.14 KB - PDF)
română (RO) (146.57 KB - PDF)
slovenčina (SK) (183.09 KB - PDF)
slovenščina (SL) (162.45 KB - PDF)
Suomi (FI) (149.94 KB - PDF)
svenska (SV) (145.54 KB - PDF)
Product details
- Name of medicine
- ProMeris Duo
- Active substance
- metaflumizone
- amitraz
- International non-proprietary name (INN) or common name
- metaflumizone
- amitraz
- Species
- Dogs
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QP53AD51
Pharmacotherapeutic group
Ectoparasiticides for topical use, incl. insecticidesTherapeutic indication
For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), and ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs.
The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Authorisation details
- EMA product number
- EMEA/V/C/000108
- Marketing authorisation holder
- Pfizer Limited
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom - Marketing authorisation issued
- 19/12/2006
- Revision
- 7
Assessment history
ProMeris Duo : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (333.17 KB - PDF)